<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<meta http-equiv="content-type" content="text/html; charset=UTF-8">

<title>Report 12079_6b_Admin_Report </title>

<link rel="stylesheet" type="text/css" href="INN_Content.css">

<script language="javascript" type="text/javascript" src="./tinymce/js/tinymce/tinymce.min.js"></script>
<script language="javascript" type="text/javascript" src="INN_JScript.js"></script>
<script language="javascript" type="text/javascript" src="datetimepicker.js"></script>
<script language="javascript" type="text/javascript" src="xmlhttp.js" ></script>





</head>
<body onload="fetchERRORMENU();showObjectError();">

<!--<input type="checkbox" name="Help_Check" id="Help_Check" value="true"/>-->
<div name="Help_Check" id="Help_Check" />
<div id="error_menu"  class="error" >This is the Help Builder </div>
<div id="menu" class="menu"></div>
<div id="Help" class="help" onMouseDown="grab(this);">
	<div class="helpitem">This is the Help Builder</div>
</div>


 
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<div ><p><img align="left" border="0" height="122" HSPACE="13" name="graphics1" SRC="./Images/WHO-EN-B-V.jpg" width="125"><br></p><h3>
  WHO International Nonproprietary Names
</h3><p><br></p><h1 lang="fr-FR" style="font-size: 14pt"><span lang="en-US">Note from WHO Secretariat on Request
  12079 (1)</span></h1><h1 align="right"><br></h1></div><p  style="BORDER-TOP:none; BORDER-BOTTOM:1px solid #000000; BORDER-LEFT:none; BORDER-RIGHT:none; PADDING-TOP:0pt; PADDING-BOTTOM:0.01in; PADDING-LEFT:0pt; PADDING-RIGHT:0pt"><br></p><p ><br></p><table  border="0" cellpadding="8" cellspacing="0" width="684"><col width="262"><col width="391"><tr valign="top"><td bgcolor="#d9d9d9" width="262"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><b>Request
        Number</b></font></font></p></td><td bgcolor="#d9d9d9" width="391"><p><font size="2">12079</font></p></td></tr><tr valign="top"><td bgcolor="#d9d9d9" width="262"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><b>Applicant
        name</b></font></font></p></td><td bgcolor="#d9d9d9" width="391"><p><font face="Arial Unicode MS, sans-serif"><font size="1"><b><p lang="en-GB" style="margin-top:0.17in">Bristol-Myers Squibb, United States of America</p></b></font></font></p></td></tr><tr valign="top"><td bgcolor="#d9d9d9" width="262"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><b>Request
        Date</b></font></font></p></td><td bgcolor="#d9d9d9" width="391"><p><font face="Arial Unicode MS, sans-serif"><font size="1"><b>2021-01-20</b></font></font></p></td></tr><tr valign="top"><td bgcolor="#d9d9d9" width="262"><p><font face="Arial Unicode MS, sans-serif"><font size="1"><font size="1">Last
        discussion in consultation n.</font></font></font></p></td><td bgcolor="#d9d9d9" width="391"><p lang="fr-FR"><font size="2"><span lang="en-US"><font size="1"><font face="Arial Unicode MS, sans-serif"><font>72 - 2021-04-13</font></font></font></span></font></p></td></tr></table><p  lang="fr-FR"><br></p><table border="0" cellpadding="8" cellspacing="0" width="684"><col width="192"><col width="460"><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><U><b>INN
				Publication</b></U></font></font></p></td><td width="460"><p lang="fr-FR"><font size="2"><b><span lang="en-US"><font size="1"><font face="Arial Unicode MS, sans-serif">Prop
				List:126 Rec List:
			   88</font></font></span></b></font></p></td></tr></table><p lang="fr-FR"><br></p><table border="0" cellpadding="8" cellspacing="0" width="684"><col width="192"><col width="49"><col width="395"><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2">Published
				Names:</font></font></p></td><td colspan="2" width="460"><table><tbody><tr><td><font face="Arial Unicode MS, sans-serif"><font size="1">Latin</font></font></td><td><font><font size="1">ispectamabum debotansinum</font></font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif"><font size="1">English</font></font></td><td><font><font size="1">ispectamab debotansine</font></font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif"><font size="1">French</font></font></td><td><font><font size="1">ispectamab débotansine</font></font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif"><font size="1">Spanish</font></font></td><td><font><font size="1">ispectamab debotansina</font></font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif"><font size="1">Arabic</font></font></td><td><font><font size="1">إيسبيكتاماب ديبوتانسين</font></font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif"><font size="1">Chinese</font></font></td><td><font><font size="1">得坦依派妥单抗</font></font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif"><font size="1">Russian</font></font></td><td><font><font size="1">испектамаб деботансин</font></font></td></tr></tbody></table></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2">CAS</font></font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif">2413386-21-5</font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2">WHO
				classification</font></font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif">L.0.0.0 / S.7.0.0</font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2">Chemical
				structure</font></font></p></td><td colspan="2" width="460"><p lang="fr-FR"><font size="2"><img border="0" src="INN_Requests/12079/Chemical_Structure/12079_9.bmp"></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2">Molecular
				formula</font></font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif">Please validate the molecular formula</font></p><p lang="fr-FR"><br></p></td></tr><tr valign="top"><td colspan="2" width="257"><p><font face="Arial Unicode MS, sans-serif"><font size="2">Pharmacological
				Action and Use</font></font></p></td><td width="395"><p><br></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="1">English</font></font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif"><p><em>immunomodulator, antineoplastic</em></p></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="1">French</font></font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif"><p><em>immunomodulateur, antinéoplasique</em></p></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="1">Spanish</font></font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif"><p><em>inmunomodulador, antineoplásico</em></p></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2">Chemical
				Description</font></font></p></td><td colspan="2" width="460"><p><br></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="1">English</font></font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif"><p>immunoglobulin G1-kappa, anti-[<em>Homo sapiens </em>TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)], humanized monoclonal antibody, conjugated at C-4 of four specific phenylalanine residues with <em>N</em><sup>2'</sup>-deacetylmaytansine via a noncleavable linker;</p>
<p>gamma1 heavy chain humanized (1-453) [VH (<em>Homo sapiens</em> IGHV3-66*01 (82.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.15] (27-34.52-59.98-112)) (1-123) -<em>Homo sapiens</em> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 Y85.2><strong>F</strong> (pAMF) (186), R120>K (220) (124-221), hinge 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364), F85.2><strong>F</strong> (pAMF) (410) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfide with kappa light chain humanized (1'-215') [V-KAPPA (<em>Homo sapiens</em> IGKV1-39*01 (84.2%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (28-33.51-53.90-98)) (1'-108') -<em>Homo sapiens</em> IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (232-232'':235-235")-bisdisulfide, produced by a cell-free protein synthesis system based on <em>Escherichia coli</em> lysate, non-glycosylated, substituted at C-4 of the <span style="font-variant: small-caps;">l</span>-phenylalanyl residues 186, 410, 186'' and 410'' with {8-[(2<em>S</em>)-1-{[(1<sup>4</sup><em>S</em>,1<sup>6</sup><em>S</em>,2<em>R</em>,3<sup>2</sup><em>S</em>,3<sup>3</sup><em>S</em>,4<em>S</em>,10<em>E</em>,12<em>E</em>,14<em>R</em>)-8<sup>6</sup>-chloro-1<sup>4</sup>-hydroxy-8<sup>5</sup>,14-dimethoxy-2,3<sup>3</sup>,7,10-tetramethyl-1<sup>2</sup>,6-dioxo-7-aza-1(6,4)-[1,3]oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl]oxy}-2,3,9-trimethyl-1,4,8,24-tetraoxo-12,15,18,21-tetraoxa-3,9,25-triazaoctacosan-28-oyl]-8,9-dihydro-1<em>H</em>(or 3<em>H</em>)-dibenzo[<em>b</em>,<em>f</em>][1,2,3]triazolo[4,5-<em>d</em>]azocin-1(or 3)-yl}methyl (<em>debotansine</em>) groups</p></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="1">French</font></font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif"><p>immunoglobuline G1-kappa, anti-[<em>Homo sapiens </em>TNFRSF17 (membre 17 de la superfamille des récepteurs du TNF, membre 17 de la superfamille des récepteurs du facteur de nécrose tumorale, antigène de maturation de cellule B, BCMA, BCM, TNFRSF13A, CD269)], anticorps monoclonal humanisé, conjugué en C-4 de quatre résidus phénylalanine spécifiques avec <em>N</em><sup>2'</sup>-déacétylmaytansine via un linker non-clivable;</p>
<p>chaîne lourde gamma1 humanisée (1-453) [VH (<em>Homo sapiens</em> IGHV3-66*01 (82.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.15] (27-34.52-59.98-112)) (1-123) -<em>Homo sapiens</em> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 Y85.2><strong>F</strong> (pAMF) (186), R120>K (220) (124-221), charnière 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364), F85.2><strong>F</strong> (pAMF) (410) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfure avec la chaîne légère kappa humanisée (1'-215') [V-KAPPA (<em>Homo sapiens</em> IGKV1-39*01 (84.2%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (28-33.51-53.90-98)) (1'-108') -<em>Homo sapiens</em> IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (232-232'':235-235")-bisdisulfure, produit par une système acellulaire de synthèse de protéines à base de lysat d'<em>Escherichia coli</em>, non-glycosylé, substitué en C-4 des résidus <span style="font-variant: small-caps;">l</span>-phénylalanyle 186, 410, 186'' et 410'' par des groupes {8-[(2<em>S</em>)-1-{[(1<sup>4</sup><em>S</em>,1<sup>6</sup><em>S</em>,2<em>R</em>,3<sup>2</sup><em>S</em>,3<sup>3</sup><em>S</em>,4<em>S</em>,10<em>E</em>,12<em>E</em>,14<em>R</em>)-8<sup>6</sup>-chloro-1<sup>4</sup>-hydroxy-8<sup>5</sup>,14-diméthoxy-2,3<sup>3</sup>,7,10-tétraméthyl-1<sup>2</sup>,6-dioxo-7-aza-1(6,4)-[1,3]oxazinana-3(2,3)-oxirana-8(1,3)-benzénacyclotétradécaphane-10,12-dién-4-yl]oxy}-2,3,9-triméthyl-1,4,8,24-tétraoxo-12,15,18,21-tétraoxa-3,9,25-triazaoctacosan-28-oyl]-8,9-dihydro-1<em>H</em>(ou 3<em>H</em>)-dibenzo[<em>b</em>,<em>f</em>][1,2,3]triazolo[4,5-<em>d</em>]azocin-1(ou 3)-yl}méthyle (<em>débotansine</em>)</p></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif">Spanish</font></p></td><td colspan="2" width="460"><p><font face="Arial Unicode MS, sans-serif"><p>inmunoglobulina G1-kappa, anti-[<em>Homo sapiens </em>TNFRSF17 (miembro 17 de la superfamilia de los receptores del TNF, miembro 17 de la superfamillia de los receptores del factor de necrosis tumoral, antígeno de maduración de célula B, BCMA, BCM, TNFRSF13A, CD269)], anticuerpo monoclonal humanizado, conjugado en C-4 de cuatro residuos fenilalanina específicos con <em>N</em><sup>2'</sup>-deacetilmaitansina a través de un enlace no escindible;</p>
<p>cadena pesada gamma1 humanizada (1-453) [VH (<em>Homo sapiens</em> IGHV3-66*01 (82.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.15] (27-34.52-59.98-112)) (1-123) -<em>Homo sapiens</em> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 Y85.2><strong>F</strong> (pAMF) (186), R120>K (220) (124-221), bisagra 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364), F85.2><strong>F</strong> (pAMF) (410) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfuro con la cadena ligera kappa humanizada (1'-215') [V-KAPPA (<em>Homo sapiens</em> IGKV1-39*01 (84.2%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (28-33.51-53.90-98)) (1'-108') -<em>Homo sapiens</em> IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dímero (232-232'':235-235")-bisdisulfuro, producido por un sistema de síntesis de proteínas sin células basado en lisado de <em>Escherichia coli</em>, no glicosilado, sustituido en C-4 de los residuos de <span style="font-variant: small-caps;">l</span>-fenilalanilo 186, 410, 186'' y 410'' con grupos {8-[(2<em>S</em>)-1-{[(1<sup>4</sup><em>S</em>,1<sup>6</sup><em>S</em>,2<em>R</em>,3<sup>2</sup><em>S</em>,3<sup>3</sup><em>S</em>,4<em>S</em>,10<em>E</em>,12<em>E</em>,14<em>R</em>)-8<sup>6</sup>-cloro-1<sup>4</sup>-hidroxi-2,3<sup>3</sup>,7,10-tetrametil-8<sup>5</sup>,14-dimetoxi-1<sup>2</sup>,6-dioxo-7-aza-1(6,4)-[1,3]oxazinana-3(2,3)-oxirana-8(1,3)-bencenaciclotetradecafano-10,12-dien-4-il]oxi}-2,3,9-trimetil-1,4,8,24-tetraoxo-12,15,18,21-tetraoxa-3,9,25-triazaoctacosan-28-oil]-8,9-dihidro-1<em>H</em>(o 3<em>H</em>)-dibenzo[<em>b</em>,<em>f</em>][1,2,3]triazolo[4,5-<em>d</em>]azocin-1(o 3)-il}metil (<em>debotansina</em>)</p></font></p><p lang="pt-BR"><br></p></td></tr></table><p  lang="pt-BR"><br></p><p  style="page-break-before:always"><br></p><table  border="0" cellpadding="8" cellspacing="0" width="684"><col width="668"><tr><td valign="top" width="668"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><u><b>INN rounds
        information</b></u></font></font></p></td></tr></table><p ><br></p><table border="0" cellpadding="8" cellspacing="0" width="684"><col width="192"><col width="460"><tr valign="top"><td width="192"><p lang="fr-FR"><br></p></td><td width="460"><p lang="fr-FR"><font size="2"><b><U><span lang="en-US"><font face="Arial Unicode MS, sans-serif">Round
				number 1</font></span></U></b></font></p></td></tr><tr valign="top"><td width="192"><p><b>Consultation number</b></p><p><br></p></td><td width="460"><b><font face="Arial Unicode MS, sans-serif">72-2021-04-13</font></b></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><U>Requested
				name(s)</U></font></font></p><p><br></p></td><td width="460"><table><tbody><tr><td><font face="Arial Unicode MS, sans-serif">decobatamab dezotansine</font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif">dacnextamab dezotansine</font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif">ispectamab dezotansine</font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif">spefitamab dibotansine</font></td></tr><tr><td><font face="Arial Unicode MS, sans-serif">adcinctamab dibotansine</font></td></tr></tbody></table></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><u>WHO suggested
				name</u></font></font></p><p><br></p></td><td width="460"><p><font face="Arial Unicode MS, sans-serif">decobatamab dibotansine</font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><U>WHO
				note</U></font></font></p></td><td width="460"></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><u>WHO
				comment</u></font></font></p><p><br></p></td><td width="460"><p><font face="Arial Unicode MS, sans-serif"><p>This substance is an antibody drug conjugate (ADC) composed by a monoclonal IgG1 antibody targeting TNFRSF17 (BCMA, CD269) conjugated covalently to the dibenzocyclooctyne noncleavable linker-maytansinoid warhead.</p>
<p>It is produced using a proprietary cell free protein synthesis technology called XpressCF+<sup>®</sup> from Sutro Biopharma and it is non-glycosylated.</p>
<p>The INN request for the naked antibody was not submitted, however it was already requested to the applicant.</p>
<p>This substance is under development for the treatment Multiple myeloma. The information retrieved from Integrity is enclosed.</p>
<p>To date there are six INN for mAbs targeting TNFRSF17: <em>teclistamab (120)(82), pacanalotamab (123)(85), pavurutamab (123)(85),</em> and <em>alnuctamab (123)(85)</em>, which are bispecifics with CD3E, all in Phase I for Multiple myeloma; and <em>belantamab (118)(80) </em>and its conjugate <em>belantamab mafodotin (118)(80)</em> (the ADC form is registered for multiple myeloma).</p>
<p>Five two-word names have been suggested with the mAb containing the infix -<em>ta</em>- and the payload suffix <em>-tansine</em>. The INN Secretariat requests the chemists to confirm if indeed the conjugate is a <em>-tansine</em>.</p>
<p><span style="text-decoration: underline;">Regarding the mAb part:</span></p>
<p>The fourth one, <strong><em>spefitamab</em></strong>, may be in conflict with <em>spesolimab (119)(81), glofitamab (121)(83)</em> and <em>upifitamab rilsodotin (123)(85)</em>.<br> The fifth one, <strong><em>adcinctamab</em></strong>, may be in conflict with <em>idactamab (123)(85), fidasimtamab</em> (RN 11670) and Adcin® (<em>adapalene (64)(32), clindamycin (21)(9)</em>).</p>
<p>The second one, <strong><em>dacnextamab</em></strong>, may be available, the conflict with <em>odronextamab (121)(83) </em>and Dacnel® capsules (<em>minocycline (14)(6)</em>) seems to be small.</p>
<p>The first, <strong><em>decobatamab</em></strong>, and third, <strong><em>ispectamab</em></strong>, suggested names seem to be available.</p>
<p><span style="text-decoration: underline;">Regarding the payload:</span></p>
<p><strong><em>dezotansine</em></strong> may be in conflict with <em>nendratareotide uzatansine (124), naratuximab emtansine (114)(76) </em>and <em>dezocine (35)(16)</em>.<br> dibotansine seems to be available.</p>
<p><strong><em>decobatamab dibotansine</em></strong> is proposed. Please comment.</p></font></p><p><br></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><U>WHO
				Suggested Mode Of Action</U></font></font></p><p><br></p></td><td width="460"><p lang="en-GB"><font face="Arial Unicode MS, sans-serif"><p><em>Antineoplastics, immunomodulator</em></p></font></p><p><br></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><u>Expert's Pre-Meeting Comments</u></font></font></p></td><td width="460"><p><br></p></td></tr><tr><td colspan="2"><table border="0" cellpadding="10"><tbody><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Abboud Habib</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">decobatamab dibotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-19</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><strong>decobatamab dibotansine </strong>is acceptable</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Adisa Akinola</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">decobatamab ezditansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p>dibotansine is clos to dobutamine.</p>
<p>Mix applicant's options to obtain<strong> <em>decobatamab ezditansine</em></strong></p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Blommaert Armand</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Boucherle Benjamin</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Boudet-Dalbin Raymond</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Chatterjee Suparna</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Chui Wai-Keung</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Dominici Massimo</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Evans Adrian</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Gao Kai</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Gogtay Nithya</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Guerrero Nilka</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-08</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><strong>Decobatamab dibotansine </strong>is acceptable.</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Iddir Kamel</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">ispectamab debotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-18</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><em><strong>ispectamab debotansine</strong></em> is accpetable</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Lopez de la Rica Ana</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">ispectamab debotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-19</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><strong><em>ispectamab debotansine</em> </strong>is acceptable</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Malan Sarel F.</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">ispectamab debotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-09</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><em><strong>ispectamab debotansine</strong></em> is accpetable</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Mignot Gilles</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">decobatamab dibotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><strong><em>decobatamab dibotansine</em></strong> is acceptable.</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Nakagawa Hidehiko</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">ispectamab debotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-15</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><strong><em>ispectamab debotansine</em> </strong>is acceptable. Modification of the first word for Secretariat suggestion, that is <em>decobetamab debotansine</em>, might be an another option.</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Pasanen Markku</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-01</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><span style="font-family: Arial, sans-serif;"><span style="font-size: small;"><strong><em>decobatamab dibotansine</em></strong></span></span> if chemists agree with tansine -issue</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Penzlin Gustav</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">ispectamab debotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-09</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><span style="background-color: #ffffff;"><strong><span lang="EN-US">ispectamab debotansine</span></strong></span><span lang="EN-US"><span style="background-color: #ffffff;"> is proposed (3+4 mixed). </span><br> <span style="background-color: #ffff99;">The conjugated drug at the cleavable long linker is </span><br><span style="background-color: #ffff99;"> <em>N</em><sup>2'</sup>-deacetylmaytansine. So the stem ...<strong><em>tansine</em></strong> = </span><br><span style="background-color: #ffff99;"> 'maytansinoid derivatives, antineoplastics' is correct. </span><br> <span style="background-color: #ffffff;"><em><span style="text-decoration: underline;">Conflicts</span>:</em> </span><br><span style="background-color: #ffffff;"> (1) decobatamab ... vs. infix ...ba... = antibacterial. </span><br><span style="background-color: #ffffff;"> (2) dacnextamab ... vs. o<span style="text-decoration: underline;">d</span>ro<span style="text-decoration: underline;">nextamab</span> (121/83), </span><br><span style="background-color: #ffffff;"><span style="color: #ffffff;"> . .</span> <span style="text-decoration: underline;">Dacne</span>l® capsules (<em>minocycline</em>, 14/6). </span><br><span style="background-color: #ffffff;"> (3) ispectamab ...: No conflict found. </span><br><span style="background-color: #ffffff;"> (4) spefitamab ... vs. <span style="text-decoration: underline;">spe</span>soli<span style="text-decoration: underline;">mab</span> (119/81), glo<span style="text-decoration: underline;">fitamab</span> (121/83), </span><br><span style="background-color: #ffffff;"><span style="color: #ffffff;"> . .</span> u<span style="text-decoration: underline;">pifitamab</span> rilsodotin (123/85). </span><br><span style="background-color: #ffffff;"> (5) adcinctamab ... vs. <span style="text-decoration: underline;">idactamab</span> (123/85), fi<span style="text-decoration: underline;">dasimtamab</span> (125/--), </span><br><span style="background-color: #ffffff;"><span style="color: #ffffff;"> . .</span> <span style="text-decoration: underline;">Adcin</span>® (<em>adapalene</em>, 64/32, + <em>clindamycin</em> 21/9). </span><br><span style="background-color: #ffffff;"> <em>Second word:</em> </span><br><span style="background-color: #ffffff;"> (1,2,3) ... dezotansine vs. nendratareotide u<span style="text-decoration: underline;">zatansine</span> (124/--), </span><br><span style="background-color: #ffffff;"><span style="color: #ffffff;"> . .</span> <span style="text-decoration: underline;">dezo</span>c<span style="text-decoration: underline;">ine</span> (35)(16). </span><br><span style="background-color: #ffffff;"> (4,5) ... dibotansine vs. <span style="text-decoration: underline;">dibote</span>rm<span style="text-decoration: underline;">in</span> (89/51), </span><br><span style="background-color: #ffffff;"><span style="color: #ffffff;"> . .</span> <span style="text-decoration: underline;">Dibota</span>b® (<em>glimepiride</em>, 66/32), <span style="text-decoration: underline;">Dibotin</span>® (<em>phenformin</em>, 10/5). </span><br><span style="background-color: #ffffff;"> (6) ... ezditansine: too far from the applicant's five suggestions, </span><br><span style="background-color: #ffffff;"><span style="color: #ffffff;"> . .</span> 'di' connotes 'two', strange consonant pair 'zd' never used. </span></span></p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Rizzi Menico</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Robertson James</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">decobatamab dibotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-06</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><em><strong>decobatamab</strong><strong> dibotansine</strong></em> is acceptable (conflict with <em>dobutamine</em> is slight)</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Rodgers Jacqueline</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Rodilla Alama Vicente</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">ispectamab debotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-19</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><em><strong>ispectamab debotansine</strong></em> is supported</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Shashkova Galina V.</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Shubat Stephanie</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">decobatamab dibotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p>I accept <em><strong>decobatamab dibotansine</strong></em> as a proposed INN.</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Strnadova Colette</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">decobatamab dibotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-01</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><P>decobatamab dibotansine supported</P></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Timon Marcos</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Vidotti Carlos</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Weerasuriya Krisantha</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Weisser Karin</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">ispectamab debotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-09</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><em>ispectamab debotansine</em> is supported</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Zhongping Guo</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr></tbody></table></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><u>Advisor and Observer's  Pre-Meeting Comments</u></font></font></p></td><td width="460"><p><font face="Arial Unicode MS, sans-serif"><font size="2">(*Advisor, **Observer)</font></font></p></td></tr><tr><td colspan="2" width="100%"><table border="0" cellpadding="10"><tbody><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Kawasaki Nana*</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">ispectamab debotansine</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-18</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><em><strong>ispectamab debotansine</strong></em> is acceptable.</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Lefranc Marie-Paule*</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Manderson Tony*</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Martin Andrew*</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Pluckthun Andreas*</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Thorpe Robin*</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">decobatamab dibotansine </font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-03-08</font></span></font></p><p><font face="Arial, sans-serif"><font size="2"><p><em>decobatamab dibotansine</em> is acceptable. An INN for the unconjugated mAb is only warranted if it is to be used clinically unconjugated.</p></font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Wieniawski Witold*</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr></tbody></table></td></tr><tr><td colspan="2" width="100%"><table border="0" cellpadding="10"><tbody><tr valign="top"><td width="192"><p><font face="Arial, sans-serif"><font size="2">Moss Gerard P.**</font></font></p></td><td><p><i><font face="Arial, sans-serif"><font size="2">Please add name</font></font></i></p></td><td width="349"><p lang="fr-FR"><font size="2"><span lang="en-US"><font face="Arial, sans-serif">2021-02-25</font></span></font></p><p><font face="Arial, sans-serif"><font size="2">Please comment</font></font></p></td></tr></tbody></table></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><U>WHO Summary</U></font></font></p><p><br></p></td><td width="460"><p lang="en-GB"><font face="Arial Unicode MS, sans-serif"><p>Several experts can accept <strong><em>decobatamab dibotansine</em></strong>. However, it is highlighted that <strong><em>decobatamab</em></strong> has the -<em>ba</em>- infix for bacterial, and <strong><em>dibotansine</em></strong> is in conflict with <em>dibotermin (89)(51)</em> and <em>dobutamine (29)(13)</em>.</p>
<p><strong><em>ispectamab debotansine</em></strong> is proposed and accepted by several experts.</p></font></p><p><br></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><u>Meeting name - decision</u></font></font></p></td><td width="460"><p lang="en-GB"><font face="Arial Unicode MS, sans-serif"><font size="1">ispectamab debotansine</font></font></p></td></tr><tr valign="top"><td width="192"><p><font face="Arial Unicode MS, sans-serif"><font size="2"><U>Meeting
				Comments</U></font></font></p></td><td width="460"><p lang="en-GB"><font face="Arial Unicode MS, sans-serif"><font size="1">No additional comment</font></font></p></td></tr></table><p ><br></p><div ><p lang="fr-FR" style="margin-top:0.35in; border-top:none; border-bottom:1px solid #000000; border-left:none; border-right:none; padding-top:0pt; padding-bottom:0.01in; padding-left:0pt; padding-right:0pt"><br></p><p lang="fr-FR"><br></p><p lang="fr-FR" style="text-indent:0.3in">2024-11-27<font size="2"><font size="1"><font face="Arial, sans-serif"> Page
    </font></font><font size="1"><font face="Arial, sans-serif">1</font></font></font></p></div><table border="1px"><tbody><tr><td>
									Annex File
								</td><td><table><tbody><tr><td><a href="./INN_Requests/12079/Document_Info/12079_Add_info_20211020_RAS.pdf">12079_Add_info_20211020_RAS.pdf</a></td></tr></tbody></table></td></tr><tr><td>
									Annex File
								</td><td><table><tbody><tr><td><a href="./INN_Requests/12079/Document_Info/12079_source_20210930.pdf">12079_source_20210930.pdf</a></td></tr></tbody></table></td></tr><tr><td>
									Annex File
								</td><td><table><tbody><tr><td><a href="./INN_Requests/12079/Document_Info/12079_CAS_20210203.pdf">12079_CAS_20210203.pdf</a></td></tr></tbody></table></td></tr><tr><td>
									Annex File
								</td><td><table><tbody><tr><td><a href="./INN_Requests/12079/Document_Info/12079_Integrity.pdf">12079_Integrity.pdf</a></td></tr></tbody></table></td></tr><tr><td>
									Annex File
								</td><td><table><tbody><tr><td><a href="./INN_Requests/12079/Document_Info/12079_decobatamab_dezotansine.pdf">12079_decobatamab_dezotansine.pdf</a></td></tr></tbody></table></td></tr><tr><td>
									Annex File
								</td><td><table><tbody><tr><td><a href="./INN_Requests/12079/Document_Info/12079_0.doc">12079_0.doc</a></td></tr></tbody></table></td></tr><tr><td>
									Annex File
								</td><td><table><tbody><tr><td><a href="./INN_Requests/12079/Document_Info/12079_CAS.pdf">12079_CAS.pdf</a></td></tr></tbody></table></td></tr><tr><td>
									Annex File
								</td><td><table><tbody><tr><td><a href="./INN_Requests/12079/Document_Info/12079_Sequence.txt">12079_Sequence.txt</a></td></tr></tbody></table></td></tr></tbody></table>
<p><a href="./Report.php?Report=INN_Phase_6b_Admin_Report&Request=12079&WordDocument">Word Document</a></p></body>
</html>
